Identification

Name
Ethyl carbamate
Accession Number
DB04827
Type
Small Molecule
Groups
Withdrawn
Description

Ethyl carbamate (also known as urethan and urethane), formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.

Structure
Thumb
Synonyms
  • Aethylcarbamat
  • Aethylurethan
  • Carbamic acid ethyl ester
  • Carbamidsaeure-aethylester
  • Estane 5703
  • Ethyl ester of carbamic acid
  • Ethyl urethan
  • Ethyl urethane
  • Ethylcarbamate
  • Ethylester kyseliny karbaminove
  • Ethylurethan
  • Ethylurethane
  • O-ethyl urethane
  • O-ethylurethane
  • Uretan
  • Uretan etylowy
  • Uretano
  • Urethan
  • Urethane
  • Urethanum
External IDs
NSC-746
International/Other Brands
Leucethane / Leucothane / Pracarbamin / Pracarbamine
Categories
UNII
3IN71E75Z5
CAS number
51-79-6
Weight
Average: 89.0932
Monoisotopic: 89.047678473
Chemical Formula
C3H7NO2
InChI Key
JOYRKODLDBILNP-UHFFFAOYSA-N
InChI
InChI=1S/C3H7NO2/c1-2-6-3(4)5/h2H2,1H3,(H2,4,5)
IUPAC Name
ethyl carbamate
SMILES
CCOC(N)=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ethyl carbamate.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Ethyl carbamate.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ethyl carbamate.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Ethyl carbamate.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Ethyl carbamate.Experimental
AdipiplonThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ethyl carbamate.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Ethyl carbamate.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethyl carbamate.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethyl carbamate.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethyl carbamate.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ethyl carbamate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Azaperone.Investigational, Vet Approved
AzelastineEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Ethyl carbamate.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ethyl carbamate.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Benzyl alcohol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Ethyl carbamate.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethyl carbamate.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethyl carbamate.Approved, Investigational
BuprenorphineEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethyl carbamate.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethyl carbamate.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Ethyl carbamate.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethyl carbamate.Approved, Illicit, Vet Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ethyl carbamate.Approved
CanertinibThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ethyl carbamate.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Ethyl carbamate.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ethyl carbamate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethyl carbamate.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Ethyl carbamate.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethyl carbamate.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethyl carbamate.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethyl carbamate.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethyl carbamate.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethyl carbamate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ethyl carbamate.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ethyl carbamate.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ethyl carbamate.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethyl carbamate.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Ethyl carbamate.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Ethyl carbamate.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethyl carbamate.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethyl carbamate.Approved
DesipramineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Ethyl carbamate.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethyl carbamate.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ethyl carbamate.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethyl carbamate.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Ethyl carbamate.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ethyl carbamate.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Difenoxin.Approved, Illicit
DigitoxinDigitoxin may decrease the cardiotoxic activities of Ethyl carbamate.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Ethyl carbamate.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethyl carbamate.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethyl carbamate.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethyl carbamate.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethyl carbamate.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethyl carbamate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dixyrazine.Experimental
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ethyl carbamate.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Ethyl carbamate.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl carbamate.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Ethyl carbamate.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ethyl carbamate.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ethyl carbamate.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethyl carbamate.Approved
EthanolEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethyl carbamate.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ethotoin.Approved
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ethyl carbamate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ethyl carbamate.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethyl carbamate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Ethyl carbamate.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethyl carbamate.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethyl carbamate.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ethyl carbamate.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ethyl carbamate.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethyl carbamate.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethyl carbamate.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethyl carbamate.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ethyl carbamate.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethyl carbamate.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ethyl carbamate.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Gepirone.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Ethyl carbamate.Experimental
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Ethyl carbamate.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Ethyl carbamate.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethyl carbamate.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Ethyl carbamate.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Ethyl carbamate.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethyl carbamate.Approved
HydrocodoneEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethyl carbamate.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ethyl carbamate.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethyl carbamate.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ethyl carbamate.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Lamotrigine.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Ethyl carbamate.Experimental
LevetiracetamThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ethyl carbamate.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethyl carbamate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethyl carbamate.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ethyl carbamate.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Ethyl carbamate.Approved
LofentanilThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethyl carbamate.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethyl carbamate.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethyl carbamate.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Ethyl carbamate.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethyl carbamate.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethyl carbamate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethyl carbamate.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ethyl carbamate.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Ethyl carbamate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ethyl carbamate.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethyl carbamate.Approved
MethotrimeprazineEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethyl carbamate.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Ethyl carbamate.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethyl carbamate.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Ethyl carbamate.Experimental
MetyrosineEthyl carbamate may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethyl carbamate.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Approved, Investigational
MirtazapineEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Ethyl carbamate.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ethyl carbamate.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethyl carbamate.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethyl carbamate.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ethyl carbamate.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethyl carbamate.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Ethyl carbamate.Experimental, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ethyl carbamate.Approved
OpiumThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Opium.Approved, Illicit
OrphenadrineEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Osanetant.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Ethyl carbamate.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethyl carbamate.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ethyl carbamate.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ethyl carbamate.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethyl carbamate.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethyl carbamate.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ethyl carbamate.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethyl carbamate.Approved
ParaldehydeEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethyl carbamate.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ethyl carbamate.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Approved
PerazineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethyl carbamate.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Ethyl carbamate.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethyl carbamate.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethyl carbamate.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethyl carbamate.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pomalidomide.Approved
PramipexoleEthyl carbamate may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Ethyl carbamate.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ethyl carbamate.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Ethyl carbamate.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Ethyl carbamate.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethyl carbamate.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ethyl carbamate.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ethyl carbamate.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ethyl carbamate.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Propoxycaine.Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Ethyl carbamate.Experimental
ProtriptylineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Ethyl carbamate.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethyl carbamate.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethyl carbamate.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethyl carbamate.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethyl carbamate.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethyl carbamate.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Romifidine.Vet Approved
RopiniroleEthyl carbamate may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethyl carbamate.Approved
RotigotineEthyl carbamate may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ethyl carbamate.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethyl carbamate.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethyl carbamate.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Approved
StiripentolThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethyl carbamate.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethyl carbamate.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Sultopride.Experimental
SuvorexantEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethyl carbamate.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tetrodotoxin.Investigational
ThalidomideEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethyl carbamate.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Ethyl carbamate.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ethyl carbamate.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethyl carbamate.Approved
TiagabineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethyl carbamate.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ethyl carbamate.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethyl carbamate.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Ethyl carbamate.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ethyl carbamate.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethyl carbamate.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethyl carbamate.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethyl carbamate.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Ethyl carbamate.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethyl carbamate.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethyl carbamate.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Zolazepam.Vet Approved
ZolpidemEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ethyl carbamate.Approved
ZotepineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethyl carbamate.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Norton A. Cashen, "Method of producing anhydrous crystalline reaction products of formaldehyde and methyl-, ethyl carbamate." U.S. Patent US4002668, issued July, 1973.

US4002668
General References
Not Available
External Links
Human Metabolome Database
HMDB31219
KEGG Compound
C01537
PubChem Compound
5641
PubChem Substance
46505215
ChemSpider
5439
ChEBI
17967
ChEMBL
CHEMBL462547
Wikipedia
Urethane

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)49 °CPhysProp
boiling point (°C)185 °CPhysProp
water solubility4.8E+005 mg/L (at 15 °C)SEIDELL,A (1941)
logP-0.15HANSCH,C ET AL. (1995)
logS0.85ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility371.0 mg/mLALOGPS
logP-0.14ALOGPS
logP-0.054ChemAxon
logS0.62ALOGPS
pKa (Strongest Acidic)15.47ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area52.32 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity20.84 m3·mol-1ChemAxon
Polarizability8.64 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9922
Caco-2 permeable+0.516
P-glycoprotein substrateNon-substrate0.892
P-glycoprotein inhibitor INon-inhibitor0.9593
P-glycoprotein inhibitor IINon-inhibitor0.9677
Renal organic cation transporterNon-inhibitor0.9397
CYP450 2C9 substrateNon-substrate0.8579
CYP450 2D6 substrateNon-substrate0.7888
CYP450 3A4 substrateNon-substrate0.7321
CYP450 1A2 substrateNon-inhibitor0.5553
CYP450 2C9 inhibitorNon-inhibitor0.9306
CYP450 2D6 inhibitorNon-inhibitor0.9168
CYP450 2C19 inhibitorNon-inhibitor0.9537
CYP450 3A4 inhibitorNon-inhibitor0.9765
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9452
Ames testAMES toxic0.7773
CarcinogenicityNon-carcinogens0.6285
BiodegradationReady biodegradable0.6313
Rat acute toxicity1.6607 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9864
hERG inhibition (predictor II)Non-inhibitor0.9783
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.45 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-01r7-9000000000-ba57e1f4b939a6bb2c1c
GC-MS Spectrum - EI-BGC-MSsplash10-01r7-9000000000-4905daa85aa870eff5d7
Mass Spectrum (Electron Ionization)MSsplash10-01r7-9000000000-dbaaf921e6f73cb42292
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as carboximidic acids and derivatives. These are compounds containing a carboximidic group, with the general formula R-C(=NR1)OR2.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboximidic acids and derivatives
Sub Class
Not Available
Direct Parent
Carboximidic acids and derivatives
Alternative Parents
Organopnictogen compounds / Organooxygen compounds / Imines / Hydrocarbon derivatives
Substituents
Carboximidic acid derivative / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative / Organooxygen compound / Organonitrogen compound / Imine / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
carbamate ester (CHEBI:17967) / a small molecule (URETHAN)

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Phospholipase a2 activity
Specific Function
Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory...
Gene Name
PLA2G4A
Uniprot ID
P47712
Uniprot Name
Cytosolic phospholipase A2
Molecular Weight
85238.2 Da
References
  1. Dinnes DL, Santerre JP, Labow RS: Phospholipase A2 pathway association with macrophage-mediated polycarbonate-urethane biodegradation. Biomaterials. 2005 Jun;26(18):3881-9. [PubMed:15626436]
  2. Labow RS, Santerre JP, Waghray G: The effect of phospholipids on the biodegradation of polyurethanes by lysosomal enzymes. J Biomater Sci Polym Ed. 1997;8(10):779-95. [PubMed:9297603]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Peroxidase activity
Specific Function
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production o...
Gene Name
MPO
Uniprot ID
P05164
Uniprot Name
Myeloperoxidase
Molecular Weight
83867.71 Da
References
  1. Kotanidou A, Choi AM, Winchurch RA, Otterbein L, Fessler HE: Urethan anesthesia protects rats against lethal endotoxemia and reduces TNF-alpha release. J Appl Physiol (1985). 1996 Nov;81(5):2305-11. [PubMed:8941558]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xanthine dehydrogenase activity
Specific Function
Oxidase with broad substrate specificity, oxidizing aromatic azaheterocycles, such as N1-methylnicotinamide and N-methylphthalazinium, as well as aldehydes, such as benzaldehyde, retinal, pyridoxal...
Gene Name
AOX1
Uniprot ID
Q06278
Uniprot Name
Aldehyde oxidase
Molecular Weight
147916.735 Da
References
  1. Sugihara K, Kitamura S, Tatsumi K: Involvement of liver aldehyde oxidase in conversion of N-hydroxyurethane to urethane. J Pharmacobiodyn. 1983 Sep;6(9):677-83. [PubMed:6689178]

Drug created on September 11, 2007 14:32 / Updated on November 09, 2017 03:47